Crew Capital Management Ltd. Takes $284,000 Position in Amgen Inc. (NASDAQ:AMGN)

Crew Capital Management Ltd. acquired a new stake in Amgen Inc. (NASDAQ:AMGN) during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 985 shares of the medical research company’s stock, valued at approximately $284,000.

A number of other hedge funds have also modified their holdings of the company. BIP Wealth LLC raised its holdings in shares of Amgen by 2.6% in the 4th quarter. BIP Wealth LLC now owns 1,249 shares of the medical research company’s stock valued at $360,000 after buying an additional 32 shares during the period. Southland Equity Partners LLC raised its holdings in shares of Amgen by 2.3% in the 4th quarter. Southland Equity Partners LLC now owns 1,538 shares of the medical research company’s stock valued at $443,000 after buying an additional 34 shares during the period. Acropolis Investment Management LLC increased its holdings in Amgen by 3.5% during the 4th quarter. Acropolis Investment Management LLC now owns 999 shares of the medical research company’s stock worth $288,000 after purchasing an additional 34 shares during the period. Opal Wealth Advisors LLC increased its holdings in Amgen by 1.9% during the 4th quarter. Opal Wealth Advisors LLC now owns 1,868 shares of the medical research company’s stock worth $538,000 after purchasing an additional 34 shares during the period. Finally, Marino Stram & Associates LLC increased its holdings in Amgen by 0.7% during the 4th quarter. Marino Stram & Associates LLC now owns 4,626 shares of the medical research company’s stock worth $1,332,000 after purchasing an additional 34 shares during the period. 76.50% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

AMGN has been the topic of several recent research reports. Royal Bank of Canada restated an “outperform” rating and set a $329.00 price target on shares of Amgen in a report on Wednesday, April 3rd. TD Cowen cut their price target on Amgen from $370.00 to $360.00 and set a “buy” rating on the stock in a report on Wednesday, April 17th. The Goldman Sachs Group upped their price target on Amgen from $313.00 to $350.00 and gave the stock a “buy” rating in a report on Wednesday, February 7th. StockNews.com downgraded Amgen from a “buy” rating to a “hold” rating in a report on Thursday, March 28th. Finally, Raymond James started coverage on Amgen in a report on Thursday, March 28th. They set a “market perform” rating on the stock. Ten equities research analysts have rated the stock with a hold rating and ten have issued a buy rating to the company. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $297.40.

Amgen Price Performance

Shares of Amgen stock traded up $6.40 on Monday, hitting $276.38. The company’s stock had a trading volume of 2,678,879 shares, compared to its average volume of 2,820,901. The company has a quick ratio of 1.13, a current ratio of 1.65 and a debt-to-equity ratio of 10.14. Amgen Inc. has a 52-week low of $211.71 and a 52-week high of $329.72. The firm has a fifty day moving average price of $275.10 and a 200-day moving average price of $281.51. The company has a market capitalization of $148.24 billion, a P/E ratio of 21.62, a price-to-earnings-growth ratio of 2.61 and a beta of 0.58.

Amgen (NASDAQ:AMGN) last issued its quarterly earnings results on Tuesday, February 6th. The medical research company reported $4.71 earnings per share for the quarter, topping analysts’ consensus estimates of $4.66 by $0.05. The company had revenue of $8.20 billion for the quarter, compared to analyst estimates of $8.13 billion. Amgen had a return on equity of 154.27% and a net margin of 23.83%. The business’s revenue for the quarter was up 19.8% compared to the same quarter last year. During the same quarter in the prior year, the company posted $4.09 EPS. On average, equities research analysts expect that Amgen Inc. will post 19.43 earnings per share for the current fiscal year.

Amgen Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, June 7th. Investors of record on Friday, May 17th will be given a dividend of $2.25 per share. This represents a $9.00 annualized dividend and a yield of 3.26%. The ex-dividend date is Thursday, May 16th. Amgen’s dividend payout ratio (DPR) is 72.06%.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.